Ionis Wins FDA Approval for Zanvastro, First Disease-Modifying Treatment for Alexander Disease
Source Summary
Ionis Pharmaceuticals has received FDA approval for Zanvastro, the first disease-modifying treatment for Alexander disease, a rare and fatal neurological disorder. This approval marks the first therapeutic option designed to modify the course of the disease.
Why it matters
Zanvastro is the first treatment option to modify the disease course for Alexander disease patients, who previously had no disease-modifying therapies available.
